ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

ABT-751 in Treating Patients With Locally Recurrent or Metastatic Renal Cell (Kidney) Cancer

This study is no longer recruiting patients.

Sponsored by: Jonsson Comprehensive Cancer Center
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of ABT-751 in treating patients who have locallyrecurrent or metastaticrenal cell (kidney) cancer.

Condition Treatment or Intervention Phase
recurrent renal cell cancer
stage III renal cell cancer
Stage IV Renal Cell Cancer
 Drug: ABT-751
 Procedure: chemotherapy
Phase II

MedlinePlus related topics:  Cancer;   Cancer Alternative Therapy;   Kidney Cancer

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of ABT-751 in Patients With Locally Recurrent or Metastatic Renal Cell Cancer

Further Study Details: 

OBJECTIVES: Primary

Secondary

OUTLINE: This is an open-label, multicenter study. Patients are stratified according to prior immunotherapy (yes vs no).

Patients receive oral ABT-751 once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for up to 2 years.

PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

PATIENT CHARACTERISTICS: Age

Performance status

Life expectancy

Hematopoietic

Hepatic

Renal

Cardiovascular

Other

PRIOR CONCURRENT THERAPY: Biologic therapy

Chemotherapy

Endocrine therapy

Radiotherapy

Surgery

Other


Location Information


California
      Jonsson Comprehensive Cancer Center, UCLA, Los Angeles,  California,  90095-5907,  United States

Study chairs or principal investigators

Robert Alan Figlin, MD, FACP,  Principal Investigator,  Jonsson Comprehensive Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000355121; UCLA-0308113; ABBOTT-M02-416
Record last reviewed:  May 2004
Record first received:  April 7, 2004
ClinicalTrials.gov Identifier:  NCT00080717
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2004-10-25
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act